FDA Issues Final Guidance for ANDA/PAS Amendments Under GDUFA II

The FDA released final guidance Tuesday spelling out its review goals for amendments to abbreviated new drug applications and prior approval supplements under GDUFA II.
Source: Drug Industry Daily